Results 251 to 260 of about 792,578 (312)

Editorial: Papillomaviruses, immunity, and tumour development. [PDF]

Front Cell Infect Microbiol
Beddows S, Kann H, Mariz FC.
europepmc   +1 more source

The Long Term Effects of a 12‐Session Community Exercise Program on Health Measures in Cancer Patients

Aging and Cancer, EarlyView.
ABSTRACT Purpose To assess the long‐term effects of a community cancer exercise program on quality of life, fatigue, weight, waist circumference, physical activity levels, lower extremity strength, body mass index (BMI), heart rate, and blood pressure, across non‐metastatic and metastatic patients.
Isaac Oppong, Roozbeh Naemi
wiley   +1 more source

Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations. [PDF]

Front Immunol
Konopka EN, Edgerton AO, Kutzler MA.
europepmc   +1 more source

Demonstration of an enhanced dosing pattern for debulking large and bulky unresectable tumors via differential hole‐size spatially fractionated radiotherapy

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose/objective We propose a novel lattice deployment for spatially fractionated radiotherapy (SFRT) treatments. In this approach, a larger diameter high‐dose sphere is centrally placed in the bulky tumor mass and surrounded by smaller diameter high‐dose spheres.
Joshua Misa, William St. Clair, Damodar Pokhrel   +2 more
wiley   +1 more source

A novel NFKB1 agonist remodels tumor microenvironment and activates dendritic cells to promote anti-tumor immunity in colorectal cancer. [PDF]

J Transl Med
Chen Y, Li Q, Wang Z, Sun LV, Hou SX.
europepmc   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice. [PDF]

Emerg Microbes Infect
Cheng X, Wang Y, Huang B, Bing J, Wang T, Han R, Huo S, Sun S, Zhao L, Shu C, Deng Y, Tan W.   +11 more
europepmc   +1 more source

CNS Mitochondria‐Derived Vesicle in Blood: Potential Biomarkers for Brain Mitochondria Dysfunction

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Mitochondrial dysfunction is a hallmark of neurodegenerative diseases like Alzheimer's (AD) and Parkinson's (PD). Our goal was to develop practical, noninvasive methods to assess mitochondrial status through the detection of mitochondria‐derived vesicles (MDVs).
Qi Liu, Wentao Chen, Yahong Wu, Zhen Guo, Jun Chen, Chen Tian, Pan Wang, Shaopeng Zeng, Bin Xu, Jing Duan, Shilong Han, Xiao Xiong, Jing Zhang   +12 more
wiley   +1 more source

Editorial: Microbiome in an immunocompromised host- a jungle of challenges or a glacier of hidden opportunities? [PDF]

Front Cell Infect Microbiol
Wojciuk B, Falcone EL, Lawson R.
europepmc   +1 more source

Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study assesses the outcomes of immunotherapy discontinuation in patients with relapsing seronegative idiopathic myelitis (SIM), a condition that remains uninvestigated due to its rarity. We reviewed records from 77 patients with relapsing SIM at the National Cancer Center of Korea, focusing on 11 who discontinued treatment after a median ...
Ki Hoon Kim, You‐Ri Kang, Jae‐Won Hyun, Su‐Hyun Kim, Ho Jin Kim   +4 more
wiley   +1 more source